CME information and disclosures
To see contributor disclosures related to this article, hover over this reference: 
Physicians may earn CME/MOC credit by searching for an answer to a clinical question on our platform, reading content in this article that addresses that question, and completing an evaluation in which they report the question and the impact of what has been learned on clinical practice.
AMBOSS designates this Internet point-of-care activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
For answers to questions about AMBOSS CME, including how to redeem CME/MOC credit, see "Tips and Links" at the bottom of this article.
Hyperphosphatemia is the abnormal elevation of serum phosphate. The majority of the body's phosphate is stored in bone, while the remainder plays a critical role in the intracellular space as part of multiple proteins and, in the form of adenosine triphosphate (ATP), as part of energy stores. Serum phosphate levels are regulated by parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), vitamin D, and calcium. The most common cause of hyperphosphatemia is chronic kidney disease (CKD). In end-stage renal disease, CKD-mineral and bone disorder (CKD-MBD) leads to dysregulation of phosphate, calcium, and PTH, resulting in secondary hyperparathyroidism. Hyperphosphatemia is often asymptomatic and diagnosed serologically. Clinical features of severe hyperphosphatemia are often related to hypocalcemia. In addition, insoluble calcium phosphate formation can lead to nephrocalcinosis and calcinosis cutis. Treatment of hyperphosphatemia centers around treating the underlying cause and may also include IV fluids, hemodialysis, and, in selected cases, pharmacotherapy (e.g., phosphate binders).
The causes of hyperphosphatemia listed below have been grouped by mechanism.
|Causes of hyperphosphatemia |
|↓ Renal excretion and/or ↑ renal reabsorption|| |
|↑ Intestinal absorption|
- Often asymptomatic
- Symptoms are often related to concomitant: 
- Hyperphosphatemia is often identified incidentally on laboratory studies.
- The diagnostic evaluation focuses on identifying the underlying cause.
If hyperphosphatemia is out of proportion to renal dysfunction, additional diagnostics should be obtained to identify the underlying cause. 
Routine studies 
Additional studies 
- Measure PTH.
- Elevated PTH : consistent with ↑ intestinal absorption, transcellular shifts, pseudohypoparathyroidism
- Normal or low PTH: Measure serum/urine calcium.
- If the cause is still unclear, consider the following:
General principles 
Consult nephrology to guide management.
- All patients
- Patients with chronic hyperphosphatemia: (e.g., resulting from CKD-MBD): Consider pharmacotherapy, including phosphate binders (e.g., sevelamer, calcium acetate).
- Patients with severe hyperphosphatemia (i.e., serum phosphate > 6.25 mg/dL)
Oral phosphate binders
- Calcium acetate 
- Aluminum hydroxide (not commonly used because of the potential for aluminum toxicity)
- Adverse effects include: nausea, vomiting, diarrhea, constipation, abdominal pain, and hypophosphatemia
Additional agents are used in the management of hyperparathyroidism.